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Alzheimer’s Disease and Type 2
Diabetes: A Critical Assessment of
the Shared Pathological Traits
Shreyasi Chatterjee* and Amritpal Mudher
Centre of Biological Sciences, University of Southampton, Southampton, United Kingdom
Alzheimer’s disease (AD) and Type 2 Diabetes Mellitus (T2DM) are two of the
most prevalent diseases in the elderly population worldwide. A growing body of
epidemiological studies suggest that people with T2DM are at a higher risk of developing
AD. Likewise, AD brains are less capable of glucose uptake from the surroundings
resembling a condition of brain insulin resistance. Pathologically AD is characterized by
extracellular plaques of Aβ and intracellular neurofibrillary tangles of hyperphosphorylated
tau. T2DM, on the other hand is a metabolic disorder characterized by hyperglycemia
and insulin resistance. In this review we have discussed how Insulin resistance in T2DM
directly exacerbates Aβ and tau pathologies and elucidated the pathophysiological traits
of synaptic dysfunction, inflammation, and autophagic impairments that are common to
both diseases and indirectly impact Aβ and tau functions in the neurons. Elucidation of
the underlying pathways that connect these two diseases will be immensely valuable for
designing novel drug targets for Alzheimer’s disease.
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INTRODUCTION
Alzheimer’s Disease: Neuropathological Alterations and
Metabolic Risk Factors
Diagnosed by the German psychiatrist and neuropathologist, Prof. Alois Alzheimer in 1906,
Alzheimer’s disease is the most prevalent form of dementia in the aging population (van der Flier
and Scheltens, 2005). Recently declared as the sixth major cause of death in the world, patients
affected with AD suffer a gradual decline of cognitive abilities and memory functions till the disease
renders them incapable of performing daily functions (James et al., 2014). Statistical data reveals
that over 30 million people are suffering from AD worldwide and this number is estimated to
double every 20 years to reach 66 million in 2030 and about 115 million by 20501.
Clinically AD can be classified into two subtypes. About 95% 0f AD patients are aged 65
years or older and are diagnosed with “late-onset” or “sporadic AD” (sAD) while 5% of AD
patients carry rare genetic mutations associated with “early-onset” or “familial AD” (fAD) that
causes the onset of disease symptoms in a person’s thirties, forties, or fifties (De Strooper, 2007).
In early onset fAD, the disease pathology is caused by mutation in three known genes namely:
amyloid precursor protein (APP), presenilin-1 (PS-1), and presenilin-2(PS-2). Although PS-1
mutations account for most of the fAD, there are mutations outside these three genes that are
yet unknown. Unlike the fAD, the genetics of sAD is more complex (Dorszewska et al., 2016).
1Available online at: https://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf.
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Other than aging, which is the strongest risk factor for
sAD, GWAS studies reveal that the epsilon four allele of the
apolipoprotein E (ApoE4) gene is a significant risk factor for the
development of this disease. Two copies of ApoE4 gene increases
risk of AD by 12-fold, while one copy of this allele enhances
the risk by 4-fold (Bertram and Tanzi, 2009). However, only 50–
60% individuals are carriers of this gene suggesting that other
factors also confer risk. Studies suggest that these include factors
such as cerebrovascular infarction, family history of diabetes,
hypertension, and obesity (Li et al., 2015a).
At a cellular level, AD is characterized by a progressive loss
of pyramidal cells in the entorhinal cortex and CA1 region
of the hippocampus that are responsible for maintenance of
higher cognitive functions (Serrano-Pozo et al., 2011). Early
symptoms of AD are also marked by synaptic dysfunction that
disrupts connectivity between neural circuits, thereby initiating
the gradual loss of memory.
Neuropathologically, AD is characterized by extracellular
plaques of insoluble amyloid-β protein, and intracellular
neurofibrillary tangles (NFTs) of hyperphosphorylated tau
protein (Iqbal et al., 2010; Serrano-Pozo et al., 2011). In AD,
abnormal cleavage of APP results in the formation of insoluble
amyloid-β protein, densely packed with beta sheets, which form
the core of the senile plaques (Serpell et al., 2000). Tau protein,
in a physiological state serves as a microtubule binding protein
and plays an important role in axonal and vesicular transport
(Mandelkow and Mandelkow, 1995). Conversely, in the disease
state tau protein is hyperphosphorylated and detached from
the microtubules. In animal models this phospho-tau-mediated
disruption of cytoskeletal integrity manifests in synaptic and
behavioral impairments (Mudher et al., 2004; Quraishe et al.,
2013; Gilley et al., 2016; Lathuilière et al., 2017). Although a
large body of in vitro studies have investigated tau-microtubule
binding interactions, most of these studies have been conducted
in silico or in non-neural cellular models (Kadavath et al.,
2015; Huda et al., 2017). In a series of elegant experiments
involving single-molecule tracking of tau in axonal processes,
Niewidok et al. and Janning et al. have shown that the
interaction of tau with the microtubules follows a “kiss-and-
hop” mechanism. Their studies show that a single tau molecule
resides only 40ms on a particular microtubule and then hops
longitudinally and transversely on adjacent microtubules. This
novel mechanism has been particularly effective in resolving
the paradoxical observation that despite regulating microtubule
dynamics, alterations in tau levels may not interfere with axonal
transport (Janning et al., 2014; Niewidok et al., 2016). Using
pseudo-hyperphosphorylated tau constructs they observed a
considerable weakening of the tau-microtubule interactions that
corroborated with previous in vitro studies.
A large body of evidence supports the idea that the formation
of Aβ plaques occurs 15–20 years earlier before the cognitive
functions decline, whereas the spatial and temporal spread of
tau pathology correlates more strongly with the severity with
disease progression (Serrano-Pozo et al., 2011; Vlassenko et al.,
2012). Although Aβ and tau are the pathological hallmarks that
characterize sAD, it is not yet clear whether these two factors
trigger AD or if they are manifested as the effect of the disease.
The drug therapy of AD is still at a nascent stage
providing symptomatic relief but not slowing down disease
progression. Such treatments include FDA-approved choline
esterase inhibitors and NMDA (glutamate) receptor agonists.
Thus, from a public health perspective AD exerts a significant
healthcare burden that is expected to escalate 5-fold in the
coming decades. Hence, the need for early detection and effective
treatment is an urgent priority (Yiannopoulou and Papageorgiou,
2013).
In recent times, it has been hypothesized that various
risk factors promote Aβ and tau-related pathological changes
before the onset of clinical symptoms in AD. One of the
formidable challenges of the twenty-first century is to identify
these risk factors and enable early detection of pathophysiological
alterations at the cellular and biochemical level so that effective
treatments can be designed against this devastating disease. A
significant risk factor associated with sAD that has received a
considerable attention in recent times is Type 2 Diabetes (T2D)
(Li et al., 2015a).
Type 2 Diabetes
Diabetes mellitus is a chronic metabolic disorder that is
increasing worldwide at an alarming rate. It is estimated that
387 million people are affected by Type1 and T2DM and this
number is expected to reach 552 million by 2030 (American
Diabetes, 2009). The financial costs for the treatment of diabetes
and support for the patients presents a significant healthcare
challenge for any country across the world.
The most prevalent subtype of diabetes is the Type 2
diabetes mellitus (T2DM) that comprises 95% of this disease.
The salient features of T2DM are high levels of blood glucose
(hyperglycaemia), hyper-insulinemia, and insulin resistance
(Taylor, 2012). Insulin resistance arises due to decreased insulin
sensitivity of muscle, liver, and fat cells to insulin. Another
prominent feature of T2DM is the formation of human islet
amyloid polypeptide that causes pancreatic β-cell dysfunction
(Marzban et al., 2003). Both these features ultimately result in
a reduced uptake of circulating blood glucose for glycogenesis
eventually leading to chronic hyperglycemia as one of the
pathological hallmarks of T2DM.
What is the evidence that there is a patho-physiological link
between Diabetes and AD?
Evidence From Epidemiological Studies
Epidemiological studies show that T2DM increases the risk of
AD by at least 2-fold (Barbagallo and Dominguez, 2014). In a
study cohort recruited from Manhattan in 1992–1994 and then
in 1999–2001 Cheng et al. demonstrated that T2DM is associated
strongly with late-onset AD (LOAD) after adjustment of sex and
age. Their findings also suggested that the link between T2DM
and LOAD is partly mediated by cerebrovascular pathology
(Cheng et al., 2011). Recent studies from Li et al. report that
T2DM in an elderly Chinese population with mild cognitive
impairment (MCI) influences the progression to AD, while no
change is observed in age-matched controls (Li et al., 2016).
These data are supported by longitudinal studies conducted by
Leibson et al. and Huang et al. in which patients with adult onset
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diabetes exhibited a significantly higher risk of developing AD
than age-matched subjects without T2DM (Leibson et al., 1997;
Huang et al., 2014). Epidemiological studies have also examined
the association between ApoE4 genotype and diabetes or insulin
resistance, although the reports are controversial. For instance,
a longitudinal study in Japanese-American men demonstrated
that ApoE4 increases the risk of LOAD in individuals with
T2DM (Peila et al., 2002). In contrast, population-based studies
conducted byMarseglia et al. show an association between T2DM
and risk of dementia only in ApoE4 non-carriers (Marseglia et al.,
2016).
Evidence From Neuroimaging Studies
The evidence from epidemiological studies has recently been
corroborated by findings from neuroimaging studies (PET and
MRI) that monitor the structural alterations in brains of patients
affected by AD and T2DM. The data from the neuroimaging
studies reveals a considerable overlap between the vulnerable
brain regions in both patient groups.
AD is generally associated with widespread brain atrophy that
initiates in the transentorhinal and entorhinal cortex in the early
stages and then spreads to the remaining neocortical areas (Fjell
et al., 2015). Neuroimaging studies show that the widespread
pattern of neurodegeneration caused by AD in the limbic and
neocortical regions correlates closely with cognitive deficits
and behavioral patterns that AD patients exhibit. However,
determining the early stages of AD pathophysiology still remains
a challenge. Recently a comprehensive study based on high-
resolution MRI on people with MCI and AD revealed that the
earliest signs of AD pathology appeared in the cholinergic cells
of the nucleus basalis of Meynert (NbM) in the basal forebrain
(Schmitz et al., 2016).
Interestingly, neuroimaging studies of brains in individuals
with T2DM also show structural alterations that resemble those
seen in AD patients. In an elegant study conducted by Moran
et al. 350 people with T2DM and 363 control individuals were
assessed for cognitive functions with an MRI scan to identify
the regional distribution of brain atrophy to identify the causes
of cognitive impairment in T2DM patients (Beckett et al., 2015;
Moran et al., 2015). The investigators found that T2DM was
associated with more cerebral infarcts and reduced volumes
of gray matter, white matter, and hippocampus compared
to non-diabetic individuals. It was further observed that in
people with T2DM, gray matter loss was most prominent in
medial temporal, anterior, cingulate, and medial frontal lobes—
the regions maximally vulnerable to AD. Moreover, cognitive
functions, and in particular visuo-spatial skills, were markedly
affected in the T2DM group. Another study by Roberts et al.
examined the associations of T2DM with imaging biomarkers
and cognitive abilities in 1,437 elderly individuals without
dementia (Roberts et al., 2014). They found that midlife T2DM
was associated with reduced hippocampal and whole brain
volumes strongly indicating decline of cognitive functions later in
life.Wennberg et al. conducted a study on 233 cognitively normal
individuals who were assessed for fasting blood glucose and
cortical thickness measurements byMRI (Wennberg et al., 2016).
This study showed that higher blood glucose was associated with
reduced average thickness in the AD vulnerable regions. Based on
these observations, the authors conclude that the brain atrophy in
T2DM, evident from imaging studies, bears striking resemblance
to that seen in preclinical AD.
Shared Pathophysiology Between AD and
T2DM
PET and MRI studies show marked impairment of glucose and
energy metabolism in both T2DM and AD (Umegaki, 2014).
In addition, amyloidogenesis remains a salient feature in both
these diseases. Extracellular β-amyloid plaques form one of the
characteristic features of AD. Likewise, deposits of amyloidogenic
peptide (IAPP) are detected in the pancreatic islets of Langerhans
of T2DM patients (Haataja et al., 2008). Interestingly, diabetic
mice overexpressing IAPP develop oligomers and fibrils with
more severe diabetic trait similar to AD mouse models that
overexpress APP (Marzban et al., 2003). Advanced glycation
end products (AGE) and their receptors (RAGE) accumulate in
the sites of diabetic complications such as kidney, retina, and
atherosclerotic plaques under conditions of ER and oxidative
stress (Nowotny et al., 2015). Similarly, glycated products of Aβ
and tau form in transgenic AD models as well as in post-mortem
brains of AD patients under similar stress conditions and form
an important component of neurofibrillary tangles (Schedin-
Weiss et al., 2014). Moreover, additional traits of synaptic
dysfunction, activation of the inflammatory response pathways
and impairment of autophagy are pathological features common
to both AD and T2DM (De Felice and Ferreira, 2014; Carvalho
et al., 2015).
The first section of this review will discuss the impact of
brain insulin resistance evident in T2DM on the two hallmarks
of AD, Aβ, and tau and describe the possible mechanisms that
interconnect AD and T2DM in the areas of synaptic dysfunction,
inflammation, and autophagic impairment (Figure 1).
ALZHEIMER’S DISEASE: INSULIN
RESISTANCE IN THE BRAIN
Brain insulin resistance is a significant, yet often over-looked
feature of AD (De Felice et al., 2014). Insulin released
from the pancreas is transported to the brain via the blood
brain barrier using a receptor-mediated mechanism. While
the crucial role of insulin response in the peripheral tissues
is well documented, there are very few reports about the
function of insulin in the central nervous system. The insulin
levels in human and rodent brain tissue are relatively low
compared to circulating levels (Talbot, 2014). There are
some reports about reduced insulin levels in the AD brains;
however, this finding was not significant compared to the
age-matched controls (Stanley et al., 2016). Recently several
studies have reported reductions of insulin mRNA in AD,
however the results of de novo insulin synthesis have been
controversial (Blázquez et al., 2014). Thus, it is hypothesized
that majority of brain insulin comes from the peripheral
tissues and the role of insulin produced in the CNS is still
unclear.
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FIGURE 1 | Overview of the diverse mechanisms by which Type 2 Diabetes can cause AD pathogenesis. Type 2 Diabetes accompanied by insulin resistance and
hyperglycemia gives rise to metabolic problems in the brain and other target tissues that sets off a cascade of pathogenic processes such as oxidative stress,
inflammatory responses, advanced glycation products and autophagic dysfunction. The reactive oxygen species generated by these pathways expedite the process
of neuronal death. At the same time, the insulin resistance impairs the downstream signaling pathways and exacerbates the formation of Aβ oligomers and aggregates
of hyperphosphorylated tau. The cumulative effect of all these factors expose the neurons to a range of assaults and gradually result in the loss of synapses and
neuronal death.
Although, the brain was initially considered a non-insulin
target organ; several studies indicate the widespread distribution
of insulin receptors (IR) in the brain particularly in the olfactory
bulb, cortex, hippocampus, and hypothalamus indicating an
intricate “neuroregulatory” role for insulin (Kim and Feldman,
2015). IRs in the brain are enriched in neurons compared to glia,
and concentrated at the synapse. However, contrary to the IRs
found in the peripheral tissues, the primary function of brain
IRs is not glucose transport and metabolism. Instead, the brain
IRs perform diverse functions including homeostatic regulation,
modulation of synaptic plasticity, and neurotransmission and age
related neurodegeneration (Plum et al., 2005).
The crucial function of glucose uptake and utilization in the
brain is carried out by Glucose transporter 4 (GLUT4). Insulin
activates GLUT4 gene expression and translocation from the
cytosol to the plasma membrane to regulate glucose homeostasis
in the brain and maintains energy requirements for a variety
neuronal functions (Chiang et al., 2001; Reno et al., 2017).
Insulin Signaling in the Brain
A large number of recent studies provide compelling evidence
that deficits in insulin signaling, arising due to insulin resistance,
occurs in AD (Talbot et al., 2012; Mullins et al., 2017). FDG-
PET studies of the brains of “early stage” AD patients have
demonstrated reduced glucose uptake leading Suzanne de la
Monte and colleagues to classify AD as “Type 3 Diabetes”(de la
Monte and Wands, 2008).
In the brain, insulin and IGF signaling mechanisms are crucial
for maintaining synaptic plasticity and cognitive functions
(Boucher et al., 2014). Once insulin binds to the IR, it is
activated by auto-phosphorylation of several tyrosine residues
which in turn activates insulin receptor substrates 1 (IRS-1)
and 2 that initiate a host of downstream signaling cascades
through phosphatidylinositol-3-kinase (PI3K) (Figure 2). PI3K
then activates AKT, which phosphorylates GSK-3β at serine 9
residue thereby inhibiting its activity and resulting in glycogen
synthesis (Avila et al., 2012). There are numerous reports that
GSK-3β is one of the key tau kinases playing a central role in
AD pathogenesis (Chatterjee et al., 2009; Hernandez et al., 2013).
Physiologically GSK-3β is involved in maintaining synaptic
plasticity and regulates NMDA receptor-mediated long-term
potentiation (LTP) and long-term depression (LTD) effects at
the synapses (Bradley et al., 2012). In the disease state however,
GSK-3β is hyperactive and phosphorylates tau at pathological
epitopes. Hyperphosphorylated tau then aggregates to form
neurofibrillary tangles (Avila et al., 2010). GSK-3β is also a key
mediator of apoptosis suggesting that it might activate neuronal
loss in degenerative diseases with increased production of Aβ (Qu
et al., 2014). Emerging data also shows that PI3K/AKT pathway
regulates synaptic plasticity by stimulating excitatory and
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inhibitory cell membrane receptors, enhances neurotransmitter
activities and increases cortical glucose metabolism in the brain
regions that are important for learning and memory (Farrar
et al., 2005). In parallel, insulin activates the MAPK pathways
leading to Ras activation at the plasma membrane and the
sequential activation of Raf, MEK, and ERK (Zhang et al.,
2011) (Figure 2). Although a direct role of the components
of the MAPK pathway in mediating AD pathology has not
yet been deciphered, recent reports indicate that ERK plays
a crucial role in synapse formation and learning/memory
functions implying that it may have additional neuroprotective
functions (Thiels and Klann, 2001). Apart from PI3K/AKT
and Ras/Raf/MAPK pathways, less well-defined roles in AD
pathogenesis are played by mammalian target of rapamycin
(mTOR) and its downstream targets that regulate neuronal
survival and nutrient sensing. mTOR regulates protein synthesis
by phosphorylating the key substrates of the translational
machinery namely the eukaryotic initiation factor 4E-binding
protein (4E-BP1) and p70S6 kinase (S6K1). Rapamycin inhibits
mTOR in vivo and halts cellular growth and proliferation
(Showkat et al., 2014).
It is hypothesized that in an insulin-resistant state these
downstream signaling pathways are compromised leading to
increased levels of Aβ oligomers and hyperphosphorylated tau
not only due to a dysregulation of the downstream kinases
but also due to an impairment of autophagic clearance that
arises as a result of imbalance of the mTOR and autophagy
pathways. Autophagic dysfunction, which is an emerging feature
of AD causes the progressive accumulation of toxic proteins and
eventually leads to neuronal death (Orr and Oddo, 2013).
From the epidemiological and brain neuroimaging studies it is
evident that insulin and IGF signaling pathways are important for
preservation andmaintenance of learning andmemory processes
that are compromised in AD. Supporting this, intranasal insulin
administration improves learning and memory functions in
AD patients, emphasizing the shared pathophysiology in both
diseases (Benedict et al., 2007).
CROSSTALK OF T2DM AND Aβ
PATHOLOGY IN AD
One of the hallmarks of AD pathology is the formation of
extracellular amyloid plaques composed of insoluble deposits
of amyloid-β protein aggregates. Aβ is generated from the
proteolytic cleavage of amyloid precursor protein (APP) by
a sequence of enzymatic reactions from BACE-1, β and
γ-secretase complex (Vassar, 2004). It is hypothesized that
lower concentration of Aβ remains in the soluble form
and subject to clearance after degradation, while higher
concentrations aggregate into insoluble plaques that are resistant
to degradation (Esparza et al., 2016). While there is no
evidence that AD brains secrete more soluble Aβ than
normal brains, a recent body of evidence suggests that an
increased accumulation of insoluble Aβ plaques arise due
to impaired clearance of Aβ protein (Wildsmith et al.,
2013).
Impact of Hyperinsulinemia on Aβ
Emerging studies indicate that hyperinsulinemia may confer
risk of AD by modulating Aβ toxicity. The enzyme responsible
for degrading the Aβ protein is Insulin Degrading Enzyme
(IDE), which also degrades insulin (Qiu and Folstein, 2006). In
T2DM, peripheral hyperinsulinemia increases the concentration
of insulin which acts as a competitive substrate for IDE and
inhibits the degradation of Aβ that gradually accumulates to
form insoluble plaques. IDE has previously been identified as
the primary regulator of Aβ in both neurons and glia (Son
et al., 2016). In a recent study Farris et al. demonstrated that
homozygous deletions of IDE gene (IDE–/–) in mice, resulted
in 50% decrease in Aβ clearance in brain homogenates and
primary neuronal cultures (Farris et al., 2003). The IDE depleted
mice exhibited increased cerebral accumulation of endogenous
Aβ, in addition to the hyperinsulinemia and glucose intolerance
that characterize T2DM. Hyperinsulinemia also affects APP
transport. In vitro studies by Gasparini et al. demonstrated
that in βAPP overexpressing N2a cells and primary neuronal
cultures, insulin decreases the intracellular accumulation of Aβ
by promoting the transport of βAPP/Aβ from the trans-golgi
network to the plasma membrane (Gasparini et al., 2001). Thus,
in addition to inhibiting the degradation of Aβ by IDE, insulin
increases the concentration of extracellular Aβ bymodulating the
trafficking of APP. The investigators also show the involvement
of receptor tyrosine kinase/mitogen-activated protein (MAP)
kinase pathway in regulating intracellular Aβ transport (Matos
et al., 2008).
Impact of Insulin Resistance on Aβ
Studies by Cheignon et al. have shown that inhibition of
PI3K leads to reduced Aβ production (Cheignon et al., 2018).
When they crossed neuron specific IR knockout mice to APP
overexpressing Tg2576 transgenicmice, this study found that loss
of insulin signaling in the brain reduced production of Aβ and
amyloid plaque deposits. However, the decrease of Aβ burden
was not sufficient to rescue the mortality observed in these
transgenic mice. Nevertheless, this data provides strong evidence
that IRS signaling plays an important role in modulating the Aβ
deposition.
Investigating the effect of diet-induced insulin resistance on
amyloidosis in Tg2576 AD transgenic mouse models, Ho et al.
found that the animals displayed the first signs of memory
deficits only at 6 months of age. These animals also maintained
normal circulating insulin levels and glucose metabolism till
they were 13 months old when there was evidence of plasma
hyperinsulinemia. Interestingly, despite high production of Aβ
and senile plaques in the brain, these mice showed no evidence
of neuronal death and neurofibrillary tangles. However when
these mice were reared on a high fat diet they developed
non-insulin dependent diabetes mellitus, that led to increased
production of Aβ40 and Aβ42, higher activation of γ-secretase
as well as GSK-3α and GSK-3β. Biochemical evidence has
shown that these mice displayed lower PI3K and AKT activation
signals denoting insulin resistance with impaired learning
and memory functions (Ho et al., 2004; Chouliaras et al.,
2010).
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FIGURE 2 | Neuronal signaling mechanisms in a state of insulin sensitivity and insulin resistance. In the insulin sensitive state insulin binds to the receptor and
activates the insulin receptor tyrosine kinase that initiates a cascade of phosphorylation events at the IRS/PI3K/AKT and Ras/Raf/ERK pathways. AKT phosphorylates
GSK-3β at the inhibitory serine 9 residue and allows tau to maintain its physiological function of binding to microtubules and facilitates normal axonal transport of
neuronal vesicles. In a state of insulin resistance, GSK-3β is activated by phosphorylation at Tyrosine 216 residue and hyperphosphorylates tau at pathological
epitopes. Hyperphosphorylated tau then detaches from the microtubules and aggregates to form neurofibrillary tangles. Likewise, in the presence of excess insulin,
the insulin degrading enzyme (IDE) is unable to degrade and facilitate clearance of Aβ oligomers that act as a competitive substrate for insulin. Thus, insulin resistance
facilitates the formation of both Aβ and tau oligomers.
Impact of Hyperglycemia on Aβ
Elevated plasma glucose levels are a common pathological feature
of T2DM affected individuals. A compelling link between glucose
metabolism and AD was established in a study conducted in
transgenic APP/PS1 murine models (Macauley et al., 2015). The
researchers observed that the induction of acute hyperglycaemia
in young mice increased the production of Aβ and lactate in
hippocampal interstitial fluid and this was associated with an
increase in neuronal activity (Minkeviciene et al., 2009). These
effects worsened in aged AD mice with increased Aβ plaque
pathology. These findings suggest that transient hyperglycemia
associated with T2DM can initiate the formation of Aβ plaques.
In this study, the authors also show that hippocampal ATP
sensitive potassium (KATP) channels act as metabolic sensors of
the alterations in glucose concentration with changes in electrical
activity and extracellular Aβ deposition.
In addition, aberrant glucose metabolism activates glycation
reactions that leads to the formation of advanced glycated end
products (AGE). Elevated AGE levels in the circulation and in
the brain have been associated with cognitive impairments in AD
patients (Li et al., 2013). Numerous studies show that there is
an increased accumulation of AGE in the brain of diabetic rats
implying that AGE products impair the removal of Aβ42 and
induce Aβ aggregation in the brain (Moreira et al., 2003).
AGEs enhance the expression of its receptor RAGE, which is
also a presumed receptor for Aβ (Srikanth et al., 2011). Recent
reports have shown increased RAGE expression in the astrocytes
and microglia of AD brains (Solito and Sastre, 2012). Also,
studies on triple transgenic model of AD (3xTg AD) expressing
3 dementia-related transgenes, namely APPSWE, PS1M146V,
and tauP301L and raised on high-fat diet as well as STZ-
induced diabetic APP/PS1 dual transgenic ADmice demonstrate
increased RAGE expression in neurons and astrocytes with an
activation of pro-inflammatory cytokines and enhanced decline
of cognitive and memory functions (Choi et al., 2014). As a
consequence of the damaging inflammatory responses, RAGE
causes vascular complications in AD and T2DM. Neuron-
specific overexpression of dominant negative RAGE results in
restoration of cognitive functions and stops the progression of
neuropathological changes in AD mice (Liu L. P. et al., 2009).
Treatment of transgenic ADmice with RAGE inhibitor decreases
microglial activation and Aβ production (Criscuolo et al., 2017).
Interestingly, soluble form of RAGE (sRAGE) is neuroprotective
(Deane et al., 2012; Lee and Park, 2013).
O-GlcNAcylation is a nucleocytoplasmic post-translational
modification that occurs abundantly in neurons and protects
against Aβ-mediated neuronal toxicity. Recent studies show
that a moderate level of O-GlcNAcylation is neuroprotective
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and decreases formation of Aβ production by inhibiting γ-
secretase activity (Hanover and Wang, 2013). Insulin resistance
and hyperglycemia increases the level of O-GlcNAcylation but
the amelioration of γ-secretase activity is counterbalanced by the
accumulation of glycated end products that are ultimately toxic
to neurons.
Impact of Dyslipidemia on Aβ
Insulin plays a crucial role in lipid metabolism and impairments
in insulin signaling lead to increased lipolysis and elevated
synthesis of free fatty acids (FFA) (Wilson and Binder, 1997).
Human brain produces approximately 30% of total body
cholesterol, hence slight alterations in lipid metabolism can have
profound effects on cognitive function. Recent studies show
that the interaction between cholesterol and APP in the plasma
membrane is necessary for Aβ synthesis and clearance. Tg2576
AD mice raised on a diet supplemented with high fat and high
cholesterol displayed increased production of Aβ. When these
animals were treated with cholesterol lowering drugs the brain
amyloid levels were reduced by more than 2-fold (Nizari et al.,
2016).
Impact of Aβ Oligomers on Insulin
Resistance
Soluble oligomers of Aβ42 have been shown to be the most toxic
species to the neurons. In the brains of AD patients with MCI,
Aβ oligomers have been shown to correlate with rapid cognitive
decline (Ferreira et al., 2015). Also, in the brain and CSF of
AD patients the level of soluble oligomers ranging from trimer
to 24-mer or higher is significantly elevated when compared to
levels found in non-demented controls (Jimenez et al., 2014).
Studies in human APP overexpressing Tg2576 AD mice show
that the onset of memory deficits correlate with production
of soluble Aβ oligomers. Small oligomers of Aβ, particularly
dimers and trimers that are formed within the neurons in vitro
are secreted into conditioned medium. The treatment of rat
hippocampal slices or live animals with these oligomers showed
potent LTP defects and cognitive deficits (Puzzo et al., 2017).
Similarly, synaptotoxicity is observed when soluble Aβ oligomers
isolated from the brains and CSF of AD patients are applied to
brain tissue slices or live animals (Minkeviciene et al., 2009).
These, inhibitory effects are blocked by Aβ antibodies and γ-
secretase inhibitors (Goure et al., 2014). This LTP blockage is
also restored by treatment with 1µM insulin (Sakono and Zako,
2010). These observations were confirmed by other investigators
who demonstrated that Aβ42 oligomers were more potent in
blocking LTP than monomers and this effect was rescued by
insulin by preventing Aβ oligomerization (Selkoe, 2008; Mucke
and Selkoe, 2012).
Recent evidence indicates an intimate connection between
brain insulin resistance and the formation of Aβ oligomers. In
a study by Zhao et al. the scientists found that the treatment of
primary hippocampal neurons by soluble Aβ oligomers results in
a profound loss of insulin receptors from the neuronal surface.
In addition, Aβ oligomers were found to increase the AKT
phosphorylation at Serine-473 residue which results in insulin
resistance (Zhao and Townsend, 2009). In addition, Aβ oligomers
inhibit insulin signaling by phosphorylating IRS1 at inhibitory
serine residues via the JNK/TNF alpha pathway (De Felice et al.,
2009). Conversely, treating AD patients and transgenic animals
with intranasal insulin lowers the concentration of soluble Aβ
and improves memory (De Felice et al., 2009). Aβ-induced
insulin resistance was also observed in the Familial AD (5XFAD)
transgenic mouse models that overexpress high levels of mutant
APP and PS1 and display severe amyloid pathology since 2
months of age (Mosconi et al., 2008).
Overall these studies demonstrate a strong impact of insulin
resistance, hyperglycemia, dyslipidemia, and other hallmarks of
T2DM on the pathological effects of Aβ amyloidogenesis as
observed in AD.
CROSSTALK OF T2DM AND TAU
PATHOLOGY IN AD
The traditional physiological function of tau protein is to
promote assembly and stabilization of microtubules, though
newer, atypical functions are now being reported (Sotiropoulos
et al., 2017). There are about 80 Ser/Thr and 5 Tyr
phosphorylation sites on tau that are phosphorylated by the key
tau kinases namely GSK-3β, MARK/PAR1, and CDK5 (Stoothoff
and Johnson, 2005; Chatterjee et al., 2009). While in the
normal brain, tau contains 2–3 moles of phosphate/mole of tau
protein; in abnormal situations as seen in AD brains and other
tauopathies, tau becomes hyperphosphorylated with 6–9 moles
of phosphate/mole of tau and aggregates to form intracellular
neurofibrillary tangles, one of the pathological hallmarks of AD
(Iqbal et al., 2010).
A wealth of emerging studies in recent years indicate
that the density of the neurofibrillary tau tangles deposited
at the neocortex of the brains of MCI patients correlated
more strongly with the severity of the disease (Bierer et al.,
1995; Nelson et al., 2012). This study showed that learning
and memory defects were more acute in patients with higher
accumulation of the tangles in the temporal lobe which is the
brain region associated with learning and memory. Thus, the
post translational modifications of tau (hyperphosphorylation,
truncation, acetylation, and glycation) and associated cellular
and biochemical changes that cause these abnormal structural
alterations are of potential interest for the development of tau
targeted therapeutic studies.
Two of the important features of T2DM namely insulin
resistance and hyperglycemia are able to influence post
translational modifications of tau and exacerbate tau pathology,
discussed below:
Impact of Insulin Resistance on Tau
Kinases and Phosphatases
Under physiological conditions, a host of kinases and
phosphatases regulate the intricate balance between tau
phosphorylation and dephosphorylation to maintain neuronal
homeostasis. Several protein kinases such as GSK-3β, CDK5,
MARK, PKA, PKB/AKT, and MAPK including ERK1/2, c-JUN
N terminal kinase (JNK) and p38 are the important kinases that
phosphorylate tau (Avila, 2008; Gómez-Sintes et al., 2011).
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Among these kinases, AKT and GSK-3β are located
downstream of one arm of the insulin signaling pathway while
components of the MAPK pathway lie downstream of the other
arm (Fröjdö et al., 2009). AKT phosphorylates GSK-3β at the
inhibitory Serine-9 residue and maintains GSK-3β in the inactive
form. However, under conditions of insulin resistance, GSK-3β is
converted to its active form by phosphorylation at Tyrosine-216
residue. Active GSK-3β then hyperphosphorylates tau to generate
the pathological epitopes AT8, AT100, and PHF1 which make
up the pre-tangles and NFTs in the AD brains (Clodfelder-Miller
et al., 2005).
Several other studies have found that p70S6 ribosomal protein
kinase—an AKT/mTOR substrate can directly phosphorylate
tau and upregulate its synthesis through phosphorylation of S6
(Yoon, 2017).
These key pathways, namely PI3K/AKT, MAPK, and
mTOR/p70S6K are regulated by insulin binding to the insulin
receptor and trigger downstream phosphorylation events (Fröjdö
et al., 2009). Thus, it is not surprising that in an insulin resistant
state, insulin is unable to activate these pathways thereby
disrupting physiological tau phosphorylation. Additionally,
in diabetic brains p38 and JNK activation can cause insulin
resistance by inhibiting the insulin receptor substrate and trigger
tau hyperphosphorylation and pathological events (Wu et al.,
2013).
Tau is also regulated by phosphatases especially PP2A that
dephosphorylates it at crucial residues Thr205, Thr212, and Ser
262 that are phospho-epitopes of GSK-3β and MARK/PAR-1.
In addition, PP2A dephosphorylates the kinases GSK-3β and
p70S6K to maintain tau phosphorylation at a physiological level
(Gratuze et al., 2017). Interestingly, several researchers have
shown a downregulation of PP2A in both T1DM and T2DM
mice suggesting that insulin resistance might exacerbate tau
phosphorylation by downregulating PP2A (Qu et al., 2011; Jung
et al., 2013).
The impact of isolated CNS-specific insulin resistance on
tau phosphorylation was investigated in vivo by Schubert
et al. using NIRKO mice where the brain/neuron specific IR
gene was conditionally inactivated. They found that NIRKO
mice displayed a complete loss of insulin-mediated PI3K/AKT
signaling resulting in reduced phosphorylation of GSK-3β at
Serine-9 and increased tau phosphorylation. However, these
animals did not exhibit any change in survival or learning
and memory defects or basal brain glucose metabolism
(Schubert et al., 2004). In another study modeling peripheral
insulin resistance in IRS2 knock out (KO) mice Schubert
and colleagues show that neurofibrillary tangles composed
of hyperphosphorylated tau aggregates accumulate in the
hippocampus of IRS2 KO mice, revealing a direct molecular
link between diabetes and Alzheimer’s disease (Schubert et al.,
2003). Likewise, Cheng et al. in IGF KO mouse brains
displayed increased tau phosphorylation at Ser-396 and Ser-
202 residues both of which are implicated in neurodegeneration
(Cheng et al., 2005). In STZ-induced Type 1 diabetic mouse
models, Planel and colleagues observed a robust increase in
tau hyperphosphorylation that prevented tau from binding to
microtubules (Planel et al., 2007). The scientists further observed
that a downregulation in the activity of PP2A in these transgenic
models exacerbated tau pathology. Similarly, Yazi and colleagues
administered STZ to induce diabetes in pR5 mice expressing
P301L mutation. Compared to non-transgenic controls, the pR5
mice displayed massive tau hyper-phosphorylation with the
formation of neurofibrillary tangles by 6 months of age (Ke
et al., 2009). In addition, other studies show that treatment of
STZ-induced diabetic mice with GSK-3β inhibitors improves
learning and memory functions (King et al., 2013). All these
studies study provide compelling evidence that both Type 1 and
Type 2 diabetes can accelerate onset and disease progression in
individuals with a predisposition to developing tau pathology.
Impact of Insulin Resistance on Tau
Cleavage
In addition to hyperphosphorylation, another abnormal post-
translational modification of tau is truncation. Tau is cleaved
by a host of proteolytic enzymes including caspases, calpains,
thrombins, and puromycin-sensitive amino peptidase. These
truncated tau fragments lack both N terminal and C terminal
fragments and form the core component of NFTs (Karsten et al.,
2006; Zilka et al., 2006).
In AD brains, caspases are activated causing tau protein to
be cleaved at several residues. The C-terminal cleavage of tau
by caspase-3 gives rise to Asp421 residue that has a higher
propensity of aggregation and is found to be associated with
neurofibrillary pathology in AD brains. The presence of Asp421
truncated tau in the neurofibrillary aggregates observed in the
neurons of double transgenic mice (Tet/GSK-3β/VLW) and in
P301Smouse models of tauopathy indicates that the formation of
Asp421 cleavage product is an important step toward formation
and maturation of tau aggregates (Basurto-Islas et al., 2008;
Gendron and Petrucelli, 2009; Gómez-Sintes et al., 2011).
Diabetes has been known to stimulate apoptosis by the
activation of caspase-3 in affected tissues (Savu et al., 2013).
Using an animal model of T2DM, Kim et al. in their studies
demonstrated an increased level of tau phosphorylation and
cleavage in the brains of db/dbmice which aremodels for diabetic
dyslipidemia (Kim B. et al., 2013). Feldman and colleagues
found that hyperglycemia promotes tau cleavage by activation
of caspases (Kim et al., 2009). Thus, these studies demonstrate
that T2DM enhances the formation of tau truncated fragments
by caspase activation that contribute toward an increased risk of
AD in diabetic patients.
Impact of Hyperglycemia on Other
Posttranslational Modifications of Tau
Acetylation is a post translational modification in which the
acetyl group from acetyl CoA is reversibly transferred to lysine
ε amino group in the tau protein. This process is modulated by
acetyltransferases and deacetylases (Cook et al., 2014). Cohen
et al. observed that tau acetylation at the key lysine residues
at K/163/280/281/369 was crucial for tau-microtubule binding
interactions and microtubule stabilization. Using cellular and
transgenic mouse models as well as human brains from a wide
spectrum of tauopathies this group has demonstrated that tau
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acetylation disrupts the tau-microtubule binding interactions
and promotes pathological tau aggregation. This group further
demonstrated that acetylated tau was associated with the
formation of insoluble tau NFTs in tau transgenic mice and
human tauopathies indicating “acetylation” as a pathogenic post-
translational modification of tau (Cohen et al., 2011).
Protein acetylation plays an important role in intermediary
metabolism and metabolic disorders including T2DM. Mass
spectrometry on STZ-induced diabetic rats showed high levels
of lysine-acetylated proteins in their kidney cells compared to
control animals (Kosanam et al., 2014). Also, treatment ofmurine
aorta cells with high glucose or FFA to induce short term diabetes
causes increased levels of lysine acetylation (Samuel et al., 2017).
Although, there are very few reports, aberrant acetylation of
tau in T2DM may interfere with the physiological functions
of microtubule binding and assembly predisposing cytoplasmic
tau toward the formation of aggregates (Irwin et al., 2013;
Trzeciakiewicz et al., 2017).
Glycosylation involves the attachment of oligosachharide
moieties to proteins and lipids. O-glycosylation is the linkage of
sugar residues to the hydroxyl groups of Serine or Threonine
residues while N-glycosylation involves attaching the sugar
moieties to the amine group of the aspargine residues in
proteins (Wang et al., 1996). Impaired OGlcNAc cycling is
implicated in AD. In post-mortem AD brains Zhu et al. have
demonstrated a significant decrease of O-GlcNAc glycosylation
of tau proteins compared to controls (Zhu et al., 2014).
Other studies from AD patients show hyperphosphorylated but
hypo-O-GlcNAc glycosylated tau implying that phosphorylation
and O-glycosylation at Serine and Threonine residues act in
opposition (Wang et al., 1996; Iqbal et al., 2010). In vitro
studies in NMR and Mass spectrometry analysis by Smet-Nocca
et al. demonstrated that tau hyper phosphorylation at residues
Ser-396 and Ser-404 were reduced by O-glycosylation at Ser-
400 (Smet-Nocca et al., 2011). Treatment of mouse models of
AD with OGA inhibitor Thiamet-G (that increases the levels
of O-GlcNAcylation of tau) was found to decrease the levels
of NFT burden and pathological tau species and slow down
disease progression (Robertson et al., 2004; Gong et al., 2005;
Yuzwa et al., 2012). However, it is interesting that Thiamet-G
decreases tau phosphorylation over a short period of time and
prolonged OGA inhibition has no effect on phosphorylation.
This is probably due to cellular adaptability over time. Compared
to O-glycosylation, in vitro studies show that N-glycosylated tau
isolated from AD brain promotes tau hyperphosphorylaton (Liu
Y. et al., 2009). Taken together these studies demonstrate that
glycosylation exerts varying effects on tau hyperphosphorylation.
Although it is still speculative, it has been hypothesized
that abnormal glucose metabolism in the brain induced by
T2DM may lead to decreased brain O-GlcNAc levels. This
reflects a failure in the neuroprotective mechanism in the brain
and triggers the cascade of tau pathology enabling disease
progression.
Impact of Tau on Insulin Resistance
While insulin resistance stimulates tau hyperphosphorylation
and aggregation, in a recent study Rodriguez-Rodriguez and
colleagues have shown that pathological alterations in tau
(hyperphosphorylation and aggregation) accumulates insulin. In
this study, the researchers have shown that insulin accumulates
in the sarcosyl-insoluble fractions of the AD brain. Moreover, the
researchers found increased accumulation of insulin in vivo in
the brains of tau overexpressing P301S mice and SHSY5Y cells as
well as in okadoic acid treated primary neuronal cultures. Both
the cells and primary neurons demonstrated increased insulin
uptake from the surroundings that eventually led to insulin
resistance (Rodriguez-Rodriguez et al., 2017). Another study
shows impaired insulin sensitivity in hippocampal slices from
tau KO mice compared to litter-mate controls (Marciniak et al.,
2017).
These studies suggest a complex relationship between tau
and insulin resistance as it is evident that not only insulin
resistance can exacerbate tau pathology but pathological tau
phosphorylation or absence of tau can affect neuronal insulin
resistance.
SYNAPTIC DYSFUNCTIONS AT THE
CROSSROADS OF AD AND T2DM
There is widespread neuronal loss and atrophy of the cortex
and hippocampus in the brains of AD patients (Sheng et al.,
2012). The cognitive failure in AD patients is accompanied
by loss in synapses and neuronal cell death with a marked
reduction in brain volumes particularly at the entorhinal cortex
and hippocampus. Although plaques and tangles characterize
the neuropathological features of AD, the closest correlation
to the severity of disease progression is the synapse loss that
occurs in the disease. There are conflicting reports as to whether
the amyloid plaques or NFTs correlate more strongly with
disease progression. Some scientists have reported that the
spatiotemporal signature of NFTs of tau correlate more severely
with the disease pathology (Nelson et al., 2012; Horvath et al.,
2013). However, investigating the “neurodegenerative triad”
Tackenberg et al. have shown that the loss of dendritic spines
and LTP that occurs early in the disease is mediated by Aβ
while the late stage cell death mediated by NMDAR requires tau
phosphorylation (Tackenberg and Brandt, 2009).
Alterations in synaptic transmission and plasticity are also
observed in the hippocampus of diabetic animal models
including depletion of synaptic vesicles at presynaptic sites and
changes of AMPA and NMDA receptors at the postsynaptic
sites. Moreover, diabetes affected the synthesis and release of
both inhibitory and excitatory neurotransmitters (Gaspar et al.,
2016). All of these factors have the potential to activate synaptic
dysfunction and widespread neuronal loss thereby predisposing
the diabetic brain to AD. In this section the impact of T2DM on
Aβ and tau mediated dysfunctions will be elaborated.
Synaptic Dysfunctions in AD
Recent studies indicate that cognitive ability in AD patients is
closely related to the alterations of the density of the presynaptic
glutamatergic boutons with an elevation of the glutamatergic
synapses in MCI patients and a gradual depletion of the boutons
with the progression of AD (Bell et al., 2007).
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Aβ and Synaptic Dysfunction
There are numerous reports that show Aβ oligomers can cause
synaptic dysfunction and toxicity (LaFerla and Oddo, 2005;
Shankar and Walsh, 2009). Under physiological conditions, low
concentration of monomeric Aβ is essential for maintaining
synaptic plasticity and neuronal survival with the improvement
of cognitive abilities. Conversely, in the disease state higher
concentration of Aβ together with aging causes synaptic
dysfunction followed by neuronal loss as seen in AD. Recent
studies show that APP and BACE1 KO mice display pronounced
defects in LTP and memory functions (Tyan et al., 2012).
Puzzo et al. showed that the treatment of mouse brain
hippocampal slices with low concentrations (200 picomoles)
of synthetic Aβ42 monomers and oligomers increased the
LTP. This study suggests that LTP is mediated by α7-nicotinic
acetylcholine receptors indicating a presynaptic role of Aβ.
Likewise, treatment with nanomolar concentration of Aβ
produced synaptic depression. This indicates that an optimal
level of Aβ is needed for synaptic transmission (Puzzo et al.,
2017).
Elevated levels of Aβ impairs glutamatergic transmission by
decreasing the number of AMPA and NMDA receptors on the
surface of the neurons. Moreover, increased concentration of
Aβ results in the internalization of NMDA receptors enhancing
LTD at the synapses. LTD causes a significant loss of dendritic
spines that is associated with early symptoms of AD and
disease progression (Palop and Mucke, 2010). EEG recording
from cortical and hippocampal networks In human APP
overexpressing mouse models shows that high levels of Aβ
oligomers elicits epileptic and nonconvulsive seizures (LaFerla
and Oddo, 2005). Consistent with these findings, in vivo
calcium imaging of cortical circuits shows that double transgenic
(hAPP/PS1) mice have a greater proportion of hyperactive
and hypoactive neurons than nontransgenic control (Palop and
Mucke, 2010; Puzzo et al., 2017). AD transgenic mice showed
an increased neuronal activity in the hippocampal regions before
the formation of insoluble amyloid plaques. On treatment with
a γ-secretase inhibitor, soluble Aβ levels were reduced and
the neuronal activity decreased implying that this effect was
a soluble Aβ-dependent effect (Busche et al., 2012). Although
the mechanisms are not completely elucidated, these studies
suggest that Aβ-dependent effects on synaptic plasticity and
neurotransmission are tightly controlled by the activation of
α7-nicotinic acetylcholine receptors or NMDARs and involves
downstream effector components including p38 MAPK and
GSK-3β (Baglietto-Vargas et al., 2016).
T2DM may trigger Aβ-mediated synaptic dysfunction
in multiple ways. Hyperinsulinemia in T2DM promotes
the formation of Aβ oligomers that cause synaptotoxicity.
Investigators have shown that when Aβ oligomers are applied
in vitro to rat hippocampal slices or in vivo to live animals
they blocked LTP and inhibited memory formation (Busche
et al., 2012). Interestingly, this effect is overcome by 1µm
insulin. A similar result was reported by Li et al. who observed
that Aβ monomers were more effective than Aβ oligomers in
inhibiting LTP and that insulin prevented Aβ-induced LTP
defects by blocking Aβ oligomerization (Balducci et al., 2010;
Li et al., 2011). Previous studies have shown that Aβ oligomers
are capable of binding to insulin receptors which causes an
impairment of receptor functions (Bradley et al., 2012; Uranga
et al., 2013). In addition, it has been shown that Aβ oligomers
alter GSK-3β phosphorylation state and directly impacts the
ERK pathway (Magrane et al., 2006; Reddy, 2013).
Tau and Synaptic Dysfunction
Recent research suggests an emerging role of tau at the synapse
(Pooler et al., 2014). Physiologically tau is localized primarily in
the axons where it binds and regulates microtubule dynamics
in a phosphorylation dependent manner (Janning et al., 2014).
However, recent isolation and analysis of AD brain-derived
synaptoneurosomes indicate that tau is present in both pre-
synaptic and post-synaptic compartments (Tai et al., 2012).
There are multiple mechanisms by which tau could mediate
synaptic function and neuronal excitability. Recent study has
shown that tau binds to the post-synaptic protein complex which
includes the PSD-95 through Fyn kinase. The interaction of
tau and Fyn appears to be crucial for directing Fyn to the
postsynaptic compartments where it can regulate the NMDA
receptor by phosphorylating one of its subunits. Abnormal tau
phosphorylation can disrupt the tau-Fyn interaction and affect
postsynaptic receptor targeting (Haass and Mandelkow, 2010).
Thus, neurons from conditionally overexpressing P301L tau
mice display impaired targeting of excitatory glutamate receptors
to dendritic spines. In addition, biochemical analysis of the
synaptosomes from these mice display a marked decrease in
the levels of synaptic markers (PSD95, Synapsin, NMDAR1, and
GluR1) implying that the loss of functional synapses plays an
important role in maintaining postsynaptic integrity (Katsuse
et al., 2006; Spires-Jones and Hyman, 2014). Electron microscopy
of NFT-carrying motor neurons in P301L mice revealed a
significant decrease in the number and size of synaptic boutons
compared to nontransgenic controls. These studies point out
that loss of synapses occur during neurodegeneration. Evidence
for tau involvement in regulating neuronal excitability comes
from a study in which a reduction in tau levels reduced
hyperexcitability in a mouse model of seizure (Holth et al., 2013;
Guerrero-Muñoz et al., 2015). Other studies have found that
neurons isolated from transgenic Tg4510 mice overexpressing
0N4R P301L mutation were more excitable than neurons from
nontransgenic mice (Kopeikina et al., 2013). However, it is worth
noting that the animal models mostly express mutant tau protein
and therefore could be more representative of FTDP-17 cases
than AD.
Although there are fewer reports, glucotoxicity in T1
and T2DM are capable of influencing tau-mediated synaptic
impairments. Investigators have shown synaptic defects and
cognitive impairments in STZ-induced diabetic models,
where genetically ablating tau ameliorated cognitive defects.
(Abbondante et al., 2014). Using a mouse model of tauopathy,
scientists have observed that under glucose-deprived conditions
as observed in hypometabolic AD brains, transgenic mice
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had impaired memory and reduced LTP accompanied by tau
hyperphosphorylation and apoptosis (Lauretti et al., 2017).
Synaptic Dysfunctions in Diabetes That
Influence Neurodegeneration
Other than directly influencing Aβ and tau-mediated synaptic
defects, diabetes also affects the synthesis and release of key
neurotransmitters that may underlie cognitive defects. For
instance under chronic hyperglycemia extracellular brain
levels of GABA and glutamate were decreased in STZ-induced
diabetic animal models (van Bussel et al., 2016). An imbalance
between excitatory and inhibitory neurotransmission impaired
the cognitive deficits observed in these animals. Diabetes
also affects acetylcholine esterase that plays a crucial role in
cognitive processes. Recent studies have shown a reduction
of cholinergic transmission in the hippocampus of STZ-
induced diabetic animals (Molina et al., 2014). Moreover,
in the STZ-induced animals, treatment of hippocampal
slices with insulin resulted in a significant decrease in the
number of NMDA receptors that consequently affected LTP
and decreased postsynaptic densities (van der Heide et al.,
2005).
Taken together these results suggest that both Type 1 and Type
2 diabetes are able to directly influence Aβ and tau-mediated
synaptic dysfunctions. In addition, both these subtypes cause an
imbalance of neurotransmitter release and alterations in synaptic
plasticity that ultimately leads to memory impairments. Hence,
synaptic dysfunctions form a shared pathological trait between
AD and T2DM.
INFLAMMATION: SHARED
PATHOPHYSIOLOGY OF AD AND T2DM
Emerging evidence in recent times points toward a compelling
link between inflammation and the pathogenesis of Alzheimer’s
disease since Aβ plaques and NFTs colocalize with glial cells
(Serrano-Pozo et al., 2011). T2DM disease pathogenesis in
particular involves high levels of ER and oxidative stress response
that might trigger the inflammatory cascade (Back and Kaufman,
2012). Additionally, misfolded toxic protein species detected
in AD and T2DM may generate oxidative stress and activate
inflammatory pathways. In this section, we discuss the role of
inflammation in AD and T2DM and how this impacts the shared
pathophysiology in both these diseases.
Inflammation and AD Pathology
Recently preclinical, genetic, and bioinformatics studies have
shown that the immune system activation accompanies AD
pathology. The genome wide association studies (GWAS)
between AD and rare mutations in the genes encoding triggering
receptor expressed on myeloid cells 2 (TREM2) and myeloid
cell surface antigen CD33 provide clear evidence that there is a
strong linkage between alterations in the immune system and the
progression of AD pathology (Griciuc et al., 2013; Ulrich et al.,
2017).
Based on the amyloid cascade hypothesis, the Aβ deposition
is followed by immune system activation mediated by glial
cells such as microglia and astrocytes. This is supported by
electron microscopy studies that show increased accumulation
of glial cells surrounding the amyloid plaque deposits in AD
brain (Wyss-Coray et al., 2003). However, recent data of
cerebrospinal fluid analysis from patients with symptoms of
MCI has demonstrated a marked alteration in the inflammatory
markers implying their involvement early in the disease pathway
(Zotova et al., 2010; Wyss-Coray, 2012). In another significant
study, scientists showed that systemic immune challenge elicited
by injecting viral mimics of polyriboinosinic-polyribocytidilic
acid resulted in “sporadic AD” like features in wild-type mouse
models accompanied by Aβ deposition, tau pathology, microglia
activation, and reactive gliosis implying that alterations in the
immune system can precede AD pathology and drive the disease
itself (Michalovicz et al., 2015). In addition, tissue microarrays
from patients with neurodegenerative diseases including AD
revealed an upregulation of inflammatory components further
suggesting an intimate linkage between inflammatory markers
and AD, early in the pathogenic cascade (Sekar et al.,
2015).
Aβ and Inflammation
In AD brains, microglia and astrocytes have been known to
accumulate around neuritic plaques and are associated with the
tissue damages that occur in AD. Aβ oligomers and fibrils are
capable of binding to receptors expressed by microglia including
CD14, CD36, CD47, a6β1 integrin, RAGE, and Toll-like
receptors (TLRs) (Doens and Fernandez, 2014). In vitro studies
have shown that binding of Aβ to RAGE receptors, helps guide
microglia to Aβ deposits and this effect is inhibited by anti-RAGE
antibodies (Wyss-Coray, 2012). Binding of Aβ to CD36 or TLR4,
on the other hand, results in the production of inflammatory
chemokines and cytokines that eventually lead to increased
neuronal damage in vulnerable regions of the AD brain (Doens
and Fernandez, 2014). Besides the secretion of inflammatory
cytokines, microglia are found to phagocytose soluble Aβ
oligomers via the extracellular proteases such as neprilysin and
insulin-degrading enzyme (IDE). However, there are evidences of
Aβ dependent impairment of microglial phagocytosis functions
in AD mouse models (Koenigsknecht and Landreth, 2004).
Recent studies have shown that microglia isolated from AD
transgenic mouse models displayed a substantial reduction in
the levels of Aβ-binding scavenger receptor and Aβ-degrading
enzyme (Zhao et al., 2017). Interestingly, it has been shown that
transient depletion of dysfunctional microglia has no impact
on Aβ deposition in an animal model of AD (Morimoto
et al., 2011). This is because microglial impairment maybe
compensated by inflammatory cytokines such as TNF, IL-
1, IL-12, and IL-23 suggesting a negative feedback loop,
that might exacerbate the AD pathology (Rubio-Perez and
Morillas-Ruiz, 2012). In addition, an upregulation in the levels
of inflammatory markers has been demonstrated in animal
models of AD or in the brains or CSF of AD patients
(Moro et al., 2018).
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Recently a huge repertoire of GWAS studies show that
structural variants of genes encoding immune receptors TREM2,
CD33, and CR1, all of which are expressed in the microglia
confer higher risk of AD (Tosto and Reitz, 2013). However,
the function of TREM2 deficiency in the progression of AD
has been controversial. For instance, while TREM2 deficiency
in APP/PS1 mice ameliorated hippocampal Aβ accumulation;
the 5XFAD mice displayed an opposite result. In these mice the
Aβ pathology was found to develop slower than APP/PS1 mice
and increased accumulation of hippocampal Aβ was observed
in the absence of TREM2 (Bemiller et al., 2017; Jay et al.,
2017). Elevated levels of soluble TREM2 was detected in the
CSF of early AD patients suggesting a change in microglial
activation in response to neuronal death. Although the exact
mechanism still remains to be deciphered, these findings show
that impaired TREM2 function plays a vital role in Aβ-mediated
AD pathogenesis.
The transmembrane protein CD33 is another microglial
receptor the structural variants of which has led to increased
risk of AD. A significant study from post mortem AD brains
has shown the upregulation of CD33 compared to age-matched
controls (Jiang et al., 2014). Conversely, the expression of a
CD33 variant, namely the protective CD33 (SNP) rs3865444 was
downregulated in AD brains and reduced insoluble Aβ deposits
(Hu et al., 2014; Li et al., 2015b).
Astrocytes too respond to AD pathogenic stimuli by
reactive gliosis. In transgenic AD mouse models exhibiting
cerebral amyloidosis the activation of astrocytes occur in the
early stages of pathogenesis. In these transgenic animals the
astrocytes underwent severe atrophy which preceded the Aβ
plaque mediated gliosis (Verkhratsky et al., 2010). Conversely,
reducing astrocytes in a transgenic Aβ overexpressing mouse
model ameliorated AD pathology (Garwood et al., 2017).
The involvement of astrocytes in neuroinflammation entails
increased production of cytokines that either affect the neurons
directly or via microglial activation (Van Eldik et al., 2016).
For instance, NFκβ-mediated activation of astrocytes release the
complement protein C3 that can bind to neuronal C3aR and
trigger neuronal damage. Another astrocyte signaling molecule
is the soluble CD40 ligand that binds to microglial cell surface
receptor. This binding interaction releases pro-inflammatory
tumor necrosis alpha (TNF-α) that has been widely reported
to contribute to tissue damage in AD (Van Eldik et al., 2016).
Astrocytes also play a neuroprotective role. Recent studies have
also shown that reactive astrocytes surrounding the Aβ plaques
take up and degrade Aβ. For instance, in Tg2576 transgenic
mice this has been shown to be linked to insulin degrading
enzyme (IDE) which plays an important role in Aβ degradation.
Reportedly, Aβ exposure of IDE enhanced the number of
activated astrocytes surrounding the neuritic plaques (Wyss-
Coray, 2012). Other studies have shown that treatment of
astrocytes with ex-vivo Aβ extracts, increase the secretion of
Aβ degrading enzymes (Wyss-Coray et al., 2003). Thus, the Aβ
pathogenesis in AD may result in alterations of normal astrocyte
functions which may be then trigger downstream inflammatory
cascades prompting further neuronal damage in AD.
Tau and Inflammation
Although there are fewer reports, in vitro studies have shown
that microglial cells stimulated by Aβ or LPS release pro-
inflammatory cytokines such as interleukin-1β and activate
tau phosphorylation at the pathological phospho-epitopes via
MAPK pathway. This was confirmed by in vivo studies in 3xTg
mouse model that displays both Aβ and tau pathologies. When
these animals were subjected to high dose of LPS treatment,
tau hyperphosphorylation was triggered at the pathological
epitopes mediated by GSK-3β, CDK5, JNK, and MAP kinases
(Barron et al., 2017). Several other studies have shown that
the activation of the key kinases CDK5 and GSK-3β by
themselves resulted in microglial activation and secretion of
IL-1β implying a close link between tau hyperphosphorylation
and pro-inflammatory markers. The gene expression profile
analysis in a mouse model of tauopathy (rTg4510) which
expresses the P301L mutation, revealed upregulation of pro-
inflammatory markers such as complement 4B, glial fibrillary
acidic protein (GFAP) and osteopontin (Spp1) on treatment with
LPS. This result confirms that neuroinflammation modulates
tau pathology in the absence of Aβ plaques (Wes et al.,
2014). In addition, TREM2 levels were decreased in these
transgenic mouse models indicating an alteration in microglial
functions (Maphis et al., 2015). In this landmark study, Bhaskar
et al. showed that LPS treatment of hTau mice expressing all
6 non-mutated tau isoforms enhanced microglial activation
and accelerated tau pathology. These mice were deficient in
microglia-specific fractalkine receptor (CX3CR1) that caused
an exacerbation of tau hyperphosphorylation via p38/MAPK
pathway. Further, studies in a P301S mutant human tau
transgenic mice demonstrated that these animals displayed
synaptic pathology and microgliosis before the onset of tangle
formation confirming that microglial activation occurs early in
the disease pathway. In this study, the researchers have shown
that the immunosuppression of young P301S transgenic mice
by FK506 significantly diminished tau pathology and increased
their lifespan (Yoshiyama et al., 2007). These studies conclude
that neuroinflammation accompanies early AD progression and
blocking neuroinflammatory pathways might be beneficial in
ameliorating tauopathies.
Hence, anti-inflammatory drugs have been used in
clinical trials to prevent disease progression in AD. A
study of nonsteroidal anti-inflammatory drugs (NSAIDS)
in a Netherlands population (Rotterdam study) showed a
significantly decreased risk of AD with increasing use of
NSAIDS. In this study the short-term use of NSAID showed
a relative risk of 0.95 while a long-term use of 24 months
or more showed a relative risk of 0.2 with a confidence
interval of 0.05–0.83 (In ’t Veld et al., 1998). In a similar study
reported in 2011 by Breitner et al. administration of NSAID
Naproxen over a period of 2–3 years decreased the incidence
of AD. These results were enhanced by measuring a marker of
neurodegeneration, CSF ratios of tau to Aβ1-42 (Breitner et al.,
2011). In contrast, a recent study by Marjerova et al. found
that LPS treatment of immortalized microglial cells in vitro
were capable of removing intracellular and extracellular tau
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oligomers by phagocytosis. These observations were validated in
vivo in C57BL/6 mice. When injected with soluble and insoluble
human tau aggregates, these mice displayed active microglial
phagocytosis of both tau species (Barron et al., 2017). Thus,
the suppression of immune system by anti-inflammatory drugs
may not prove beneficial to AD treatment in the long run as
these might enhance the spread of tau oligomers across healthy
neurons.
Inflammation in Type 2 Diabetes That
Influence Neurodegeneration
Type 2 Diabetes has been associated with excess immune system
activation, which increases the expression of proinflammatory
cytokines especially microglia in the brain. It is noteworthy that
Swaroop et al. observed elevated levels of TNFα, IL-1β, IL-
2, and IL-6 in the hippocampus of diabetic animals (Swaroop
et al., 2012). Previous studies have shown that incubation of
cells with TNFα or high levels of FFA promotes inhibitory
phosphorylation of the serine residues of IRS-1. This impairs
the ability of IRS-1 to interact with the insulin receptor and
generates an insulin-resistant condition capable of triggering Aβ
and tau pathological cascades (Peraldi et al., 1996). It has also
been demonstrated that obesity and hyperglycemia in T2DM
contributes to ER andmitochondrial stress that generates reactive
oxygen species (ROS). Elevated ROS then causes enhanced
activation of inflammatory pathways (Kaneto et al., 2010; Back
and Kaufman, 2012).
Along with evidences that relate oxidative stress and
inflammation to the pathophysiology of diabetes, studies
performed in various cellular and animal models suggest NFκβ
activation is a key event early in the disease pathobiology and its
complications. Several studies have shown that NF-κβ is induced
by hyperglycemia and in conditions of neuronal damage (Romeo
et al., 2002;Wellen andHotamisligil, 2005). The activation of NF-
κβ is followed by the expression of pro-inflammatory cytokines
that jointly trigger brain inflammation and neuronal apoptosis
eventually leading to cognitive decline. For instance, in the
hippocampus of the STZ-treated rats there is a strong increase of
ROS followed by NF-κβ activation (Locke and Anderson, 2011).
Activated NF-κβ can induce cytotoxicity, trigger inflammation
and promote apoptosis (Jaeschke et al., 2004). In STZ-induced
retinopathy rat models, NF-κβ activation has been associated
with enhanced expression of caspase 1 (Yin et al., 2017). Recent
reports show that NF-κβ might be an important regulator of
insulin sensitivity in T2DM by controlling the expression of
GLUT2 receptor which is important for glucose secretion and
transport in pancreatic beta cells (Patel and Santani, 2009).
Incidentally, the metabolic stresses that promote insulin
resistance and T2DM also activate the inflammation and stress-
induced kinases Ikβ kinase-β (IKKβ) and JUN N-terminal kinase
(JNK) suggesting that these kinases play an important role in
disease pathogenesis. Both JNK and IKκβ can phosphorylate
the IRS-1 at the inhibitory Serine 307 thereby impairing insulin
action (Jaeschke et al., 2004; Morel et al., 2010).
Oxidative stress in insulin resistance generates FFA and AGE
products which result in glucotoxicity and impairment of insulin
signaling. These ligands act through Toll-like receptors (TLRs)
and receptors for advanced glycation end products (RAGE) that
are also activated in neurodegenerative diseases (Ozcan et al.,
2004). RAGE especially acts as a putative Aβ receptor and plays a
significant role in AD pathogenesis. It is therefore predicted that
the cumulative effect of these stress factors may lead to neuronal
apoptosis and brain inflammation, both of which are prominent
features of neurodegenerative diseases including AD.
To investigate whether inflammatory pathways act as a
potential link between AD and T2DM, Takeda et al. generated a
dual model of AD and T2DM by crossing an APP23 transgenic
mice that overexpresses human APP to leptin-deficient ob/ob
mice or polygenic NSY mice as a model for diabetes. The
APP+/ob/ob dual transgenics showed increased levels of
amyloid deposition around brain microvessels and enhanced
cerebrovascular inflammation even before the manifestation
of cerebral amyloid angiopathy. (Takeda et al., 2010). The
authors also report an increased levels of RAGE in blood
vessels as well as elevated levels of TNFα and IL-6 in the
brain microvasculature of these animals. Progressive cognitive
deficits and increased cerebrovascular inflammation were also
noted in APP+-NSY dual transgenics raised on high-fat diet
compared to NSY mice raised on the same diet. In a study
conducted by Knight et al. a similar impact of high-fat diet was
observed in 3xTg AD mice that overexpress triple mutations in
human APP/MAPT-P301L/PSEN1 and in nontransgenic mice.
When raised on a high-fat diet both the transgenics and the
control animals displayed considerable weight gain and memory
impairments. However, the memory impairments were more
severe in the 3xTg mice compared to the controls. It is also
interesting that although no significant differences were observed
in the amyloid plaques and tau-tangle loads, the brains of 3xTg
animals were accompanied by severe microgliosis that was not
observed in age-matched controls. This strongly implies the role
of neuroinflammation in the development of AD pathogenesis
especially when subjected to abnormal dietary conditions (Knight
et al., 2014).
Emerging studies have shown that loss of inflammatory
mediators prevents insulin resistance, therefore pharmacological
targeting of inflammatory pathways improve insulin action.
For instance, salicylates activate insulin signaling by inhibiting
inflammatory kinases within the cell (Kim M. S. et al.,
2013). Similarly, targeting JNK using a synthetic inhibitor has
been reported to enhance insulin signaling in obese mice
and reduce atherosclerosis in ApoE mutant rodent model
(Lee et al., 2003). There are yet other studies which show
that thiazolidinediones (TZDs), high-affinity ligands of PPARγ
act as insulin sensitizing agents and improve insulin action
by activating lipid metabolism as well as by reducing the
production of inflammatory molecules like TNFα (Peraldi et al.,
1996).
These studies support a significant correlation between
hyperglycemia, impaired insulin resistance, oxidative stress,
and inflammation. All these factors are capable of directly
impacting Aβ and tau pathologies as well as triggering a chain
of inflammatory stress responses that might eventually lead to
neurodegeneration as observed in AD.
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AUTOPHAGIC IMPAIRMENTS IN AD AND
T2DM
Intracellular accumulation of misfolded protein aggregates is a
salient feature of most neurodegenerative diseases (Frake et al.,
2015). Autophagy is the process by which such protein aggregates
are cleared from the neurons and is important for maintaining
neuronal homeostasis. As neurons age they accumulate toxic
intracellular protein aggregates and damaged organelles such
as mitochondria that must be immediately cleared for the
neuron to function at a physiological level (Lee, 2012; Son
et al., 2012). Recent studies show that autophagic machinery is
also involved in the pathophysiology of T2DM and it regulates
the normal function of pancreatic beta cells. Insulin resistance
generates oxidative stress on insulin-responsive tissues, enhanced
autophagy in these cases acts as a protective factor (Masini
et al., 2009). Other than indirect effects, there are studies
that report direct impact of insulin resistance on autophagy
by an inhibition of the downstream mTOR signaling pathway
(Blagosklonny, 2013). Although, the connection between AD
and T2DM pathogenesis in terms of autophagic dysfunction
is not well documented, in this section we elaborate on the
shared pathophysiologies of autophagy malfunctioning in these
diseases and elaborate on the mechanisms by which insulin
resistance might impact autophagy impairment and exacerbate
AD pathogenesis.
Autophagy Malfunction in AD
Macroautophagy is the most prevalent form of neuronal
autophagy (Frake et al., 2015). In this process, cytoplasmic
proteins and organelles are sequestered into double membrane
bound structures called autophagosomes (Figure 3). In the
next step, the autophagosomes fuse with the lysosomes to
form autolysosomes or alternatively with endosomes to form
amphisomes before fusing with lysosomes and finally the
contents are degraded.
There is a substantial evidence that autophagy is dysregulated
in the brains of AD patients. In 2005, Nixon and colleagues
used immunogold labeling and electron microscopy techniques
on AD brain biopsies of neocortical regions and detected
diverse formations of immature autophagic vacuoles (AVs) in
the dystrophic neurites (Nixon, 2007). The same phenomenon
was also observed in transgenic animal models of AD. A
study in PS-1/APP double transgenic mice showed that AVs
were formed in dendrites and soma before the appearance of
Aβ plaques compared to age-matched control animals (Nixon
et al., 2005). Chen et al. using LC3-EGFP overexpressing
5X FAD mouse models and age-matched controls, observed
increased accumulation of autophagosomes in the neurons
of FAD-mouse models compared to the controls. This was
more prominent under conditions of starvation. Interestingly,
the macroautophagy induced by starvation in the transgenic
animals was not sufficient to degrade the endogenous Aβ
levels which resulted due to increased cellular uptake of
extracellular Aβ (Chen et al., 2015). The importance of
autophagy in the brain was highlighted in a study demonstrating
that neuron-specific loss of autophagy proteins (ATG7 and
ATG5) in mice results in neurodegeneration even when other
pathological factors are absent (Frake et al., 2015). However,
actual mechanisms underlying autophagic dysfunctions in AD
has not been fully elucidated. Till date it is a matter of
debate as to whether autophagy is the cause or a result of
AD.
Presenilins as Autophagy Modulators
Neely et al. has shown that Presenilins play an important role
in mediating autophagy as PS-1 has been shown to facilitate N-
glycosylation of V0a1 subunit of the lysosomal vacuolar ATPase
(v-ATPase) (Neely et al., 2011). FAD-associated mutations in
PS-1 and PS-2 leads to an impairment of lysosomal function
due to failed acidification of the internal lysosomal contents.
This causes an increased accumulation of autophagosomes and
a failure to fuse with dysfunctional lysosomes. In their study,
Wilson et al. found that in PS-1–/– neurons both α and β
synuclein are mislocalized to the lysosomes of the neuronal
cell body and not in the presynaptic regions. The increased
accumulation of synuclein suggests that PS-1 deficiencies play
a crucial role in developing α-syn lesions in neurodegenerative
diseases as observed in familial AD and PD (Wilson et al., 2004).
Interestingly, Tung et al. found that non-neuronal and neuronal
cells lacking PS-1 displayed reduced levels of p62 protein which
serves as a “cargo receptor” for tau degradation. Their study
suggests a novel mechanism by which the reduction PS-1 or its
mutation in FAD impairs p62-dependent tau clearance (Tung
et al., 2014).
Aβ as an Autophagy Modulator
There is a complex interplay between Aβ and autophagy.
Several studies have shown that autophagy plays a crucial role
in Aβ metabolism including Aβ production, secretion, and
degradation (Nilsson et al., 2015). Autophagy facilitates the
degradation and clearance of APP and all APP cleavage products
comprising Aβ and APP-C-terminal-fragments. Deficiency of
autophagy protein beclin 1 in cultured neurons and human
APP transgenic mice resulted in elevated intraneuronal Aβ
and formation of extracellular amyloid plaques. Overexpression
of beclin 1 promoted neuronal autophagy, reduced Aβ levels,
and ameliorated neurodegeneration (Pickford et al., 2008).
Autophagy may also play a role in the secretion of Aβ into
extracellular environment where it causes plaque formation. For
instance, deletion of ATG7 in APP transgenic mice resulted
in less amount of Aβ secretion and plaque formation (Xiong,
2015).
Interestingly, Aβ by itself could also be a regulator
of autophagy as intracellular Aβ can activate autophagy
by an AKT-dependent pathway or RAGE-CAMκβ-AMPK
pathway by induction of mitochondrial ROS generation (Kim
et al., 2017). Thus rapamycin, an mTOR inhibitor that
upregulates autophagy, is able to reduce both Aβ pathology
in AD mouse models and improve cognition (Spilman et al.,
2010).
Several studies indicate that insulin resistance in T2DM
inhibits the downstream mTOR pathway and activates
autophagy. Insulin resistance also causes ER and oxidative
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FIGURE 3 | Insulin signaling also controls mTOR pathway that inhibits autophagy. Both insulin resistance in Type 2 Diabetes and Alzheimer’s disease impairs the
formation of autophagosomes and disrupts lysosomal function. Autophagosomes fuse with lysosomes to form autolysosomes. These autolysosomes have impaired
lysosomal function in AD and T2DM and accumulate Aβ and tau aggregates. Undigested toxic aggregates are secreted out of the neurons and propagate toxic
oligomers in adjacent neurons.
stress that are capable of inducing autophagy (Quan et al., 2012).
Ideally, enhanced autophagy should facilitate Aβ clearance;
however, studies in ATG7 mouse models have shown that
increased autophagy may also cause an increased secretion of
Aβ in the extracellular matrix and enhance the deposition of Aβ
plaques (Inoue et al., 2012). Thus, activation of autophagy under
conditions of insulin resistance may worsen Aβ-mediated AD
pathogenesis.
Tau and Autophagic Dysfunction
Recent studies suggest that autophagy plays a vital role in tau
protein degradation and clearance (Inoue et al., 2012). A study
in autophagy-impaired Nrf2 KO mice shows that the levels of
phosphorylated and sarcosyl-insoluble tau increases (Jo et al.,
2014). In ATG7 conditional KO mouse models the loss of ATG7
from the forebrains of transgenic mice leads to an accumulation
of phospho-tau resembling pre-tangle formation within neurons
(Inoue et al., 2012). On the restoration of autophagy, the levels
of phospho-tau was found to be diminished. It has also been
shown that the full-length tau (2N4R) and the caspase cleaved
version (tauδC) are preferentially degraded by macroautophagy,
while the truncated version of tau (taudelta280) is translocated
to lysosomes by cell mediated autophagy (CMA) pathway (Dolan
and Johnson, 2010).
Recent studies in primary neurons and transgenic P301S
mouse models have demonstrated that treatment with
autophagy-inducers trehalose and rapamycin reduced insoluble
tau levels (Schaeffer et al., 2012; Ozcelik et al., 2013). Conversely,
other studies have shown that mammalian target of rapamycin
(mTOR) impairs tau clearance by inhibiting autophagy. The
TSC1 and TSC2 are negative regulators of mTOR. Consequently,
in TSC–/– transgenic mice the elevated levels of endogenous total
and phosphorylated tau suggests an impairment of autophagy
(Caccamo et al., 2013; Steele et al., 2013).
Under physiological conditions, tau promotes microtubule
assembly and regulates microtubule dynamics (Janning et al.,
2014). The microtubular arrays provide tracks for retrograde
trafficking and maturation of autophagosomes before fusing
with lysosomes in the soma (Kononenko, 2017). In the disease
state, hyperphosphorylated tau is capable of disassembly and
breakdown of microtubules that could subsequently inhibit
retrograde trafficking causing the accumulation of immature
autophagosomes within the axons (Rodríguez-Martín et al.,
2013).
Autophagic Dysfunction in T2DM That Can
Trigger AD Pathogenesis
Insulin resistance in T2DM effectively results in increased
oxidative stress that causes the production of ROS leading to
damage of intracellular organelles such as ER and mitochondria
(Jung et al., 2011). These ER and mitochondrial stress factors
are the critical upstream events for the induction of downstream
autophagic pathways for the removal and clearance of misfolded
proteins in the ER lumen and the dysfunctional ER and
mitochondria (Quan et al., 2012). However, during prolonged
periods of intracellular stress autophagy pathway becomes
inefficient leading to increased accumulation of autophagosomes
and impaired clearance. In vivo studies in pancreatic beta-cell
specific ATG7 KO mice have shown a decrease in the number of
pancreatic beta-cells, impaired glucose tolerance, and reduction
in insulin secretion (Chen et al., 2011). In addition, these
cells accumulate large ubiquitinated proteinaceous materials
and p62 implying an autophagic impairment. Supporting
these observations, Fujitani et al. demonstrated an increased
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accumulation of autophagosomes in the pancreas of db/db mice
(Fujitani et al., 2009). In addition, these ATG7-null beta-cells
were found to be apoptotic leading to a decreased beta cell mass.
When these ATG7 KOmice were crossed to ob/ob mice (a model
for obesity with a mutation in the leptin gene) the progeny
displayed severe diabetes suggesting that autophagic impairment
in obese animals might make them more susceptible to diabetes
(Quan et al., 2012). These studies suggest that autophagy acts as
a neuroprotective factor in response to ER and mitochondrial
stress generated in T2DM.
To elucidate the autophagic impairments underlying AD and
T2DM, Jung et al. compared tau pathology and its associated
signaling pathways in diabetic OLEF rats and age-matched non-
diabetic controls (Jung et al., 2011). The scientists observed
an increased accumulation of total and phospho-tau in the
soluble fractions of brain extracts from OLEF rats. Interestingly,
the increased accumulation of polyubiquitinated tau protein
in the neurons of OLEF rats was accompanied by a decrease
in p62 protein levels that is responsible for degradation of
ubiquitinated tau by autophagy and proteasomal pathways
In a similar study by Carvalho et al. using 3xTgAD and
T2DM mouse models, a significant reduction was observed
in the levels of autophagy markers ATG7 and LC3-II in the
cerebral cortex and hippocampus of both these mice (Carvalho
et al., 2015). Pronounced behavioral deficits were observed
in these animals that correlated strongly with a reduction
of the autophagy markers including the lysosomal marker
LAMP1 suggesting an accumulation of autophagosomes and
impaired protein clearance in both these models. It can be
inferred that the impaired clearance of toxic, soluble aggregates
of hyperphosphorylated tau protein is a critical mechanism
underlying increased AD-like pathology in T2DM.
Taken together, these results show that firstly insulin resistance
in T2DM is capable of inducing prolonged period of oxidative
stress which leads to the failure of autophagic machinery and
impaired autophagic clearance. This in turn may lead to the
progressive build-up of toxic protein aggregates such as Aβ
and tau oligomers and trigger AD pathogenesis. Secondly,
under abnormal metabolic conditions or aging, autophagic
impairment might be a crucial risk factor for T2DM. This
could lead to a viscous cycle in which T2DM can promote
tau hyperphosphorylation and induce the accumulation of
autophagosomes within the neurons. Impaired autophagic
clearance then triggers neurodegenerative events that lead to AD
pathogenesis. The crucial role played by autophagy in AD and
T2DMopens a new chapter in the development of pro-autophagy
drugs that would be used as part of combinatorial therapy in
targeting both diseases.
CONCLUSION
In this review we have attempted to summarize the growing body
of research that depicts the shared pathophysiology of AD and
T2DM and elaborated on the underlying mechanistic pathways
at the crossroads of these two diseases. However, it should be
noted that almost all the animal models of Aβ and tau that
have been used for preclinical studies are based on FTDP-17
cases and not on sporadic AD models. Although the mechanistic
uderpinnings that link AD and T2DM could be similar, there is
a possibility of considerable variation in the development and
propagation of the disease pathology in the familial vs. sporadic
cases. This is particularly relevant when designing combinatorial
therapies.
A growing body of evidence suggests that the structural
and functional integrity of the CNS is compromised in
T2DM in the presence of excess insulin or under a condition
of insulin resistance. In addition, T2DM impairs glucose
metabolism and generates oxidative stress in vital cell organelles.
Insulin resistance which is a prominent feature of T2DM
is capable of increasing the production and secretion of Aβ
by decreasing proteolysis by IDE. Also, insulin resistance
dysregulates the PI3K/AKT/GSK-3β signaling cascade and
generates hyperphosphorylated tau. Insulin resistance leads to
loss of synapses, impaired autophagy and increased neuronal
apoptosis. These alterations might trigger a cascade of events
leading to abnormal Aβ and tau accumulation culminating in
Alzheimer’s disease pathology. Hence, targeting brain insulin
signaling with pharmacological therapies used for treating
T2DM is a novel and compelling approach to treat AD
(Morris and Burns, 2012). This has given way to “drug-
repositioning” strategies in which pre-existing anti-diabetic
drugs are subjected to clinical trials to test their efficacy
in AD therapeutics (Watson et al., 2005; Chen et al.,
2009; Miller et al., 2011; Moore et al., 2013; Yarchoan and
Arnold, 2014; Luchsinger et al., 2016; Femminella et al.,
2017).
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